establishing-competing-risk-regression-nomogram-model-for-survival

Establishing a Competing Risk Regression Nomogram Model for Survival Data

The Kaplan&#8211;Meier method and Cox proportional hazards regression model are the most common analyses in the survival framework. These are relatively ...

an-r-based-landscape-validation-of-a-competing-risk-model

An R-Based Landscape Validation of a Competing Risk Model

The Cox proportional hazard model is widely applied for survival analyses in clinical settings, but it is not able to cope with multiple survival ...

Zhejiang University School of Medicine

This study was performed to identify a reasonable cutoff age for defining older patients with colorectal cancer (CRC) and to examine whether old age was related with increased colorectal cancer-specific death (CSD) and poor colorectal cancer-specific survival (CSS).

Impact of old age on resectable colorectal cancer outcomes.

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disorder arising from mutations of the MEN1 tumor suppressor gene on chromosome 11q13; MEN1 is characterized by the development of neuroendocrine tumors, including those of the parathyroid, gastrointestinal endocrine tissue and anterior pituitary. Additionally, thymic neuroendocrine tumors in MEN1 are also rarely reported.

p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report.

More than half of early breast cancer recurrences occur after 5 years from the initial diagnosis. An individualized estimate of the risk of late-period breast cancer-specific death (LP-BCSD) after 5 years of endocrine therapy (ET) can improve decision-making for extended endocrine therapy (EET).

Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer.

The single progesterone receptor (PR)-positive phenotype (estrogen receptor (ER)-/PR + , sPR positive) is an infrequent and independent biological entity. However, the prognosis of patients with sPR-positive and her-2-negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them.

Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.

Hongjuan Zheng

Department of Medical Oncology,
Affiliated Jinhua Hospital,
Department of Medical Oncology, Affiliated Jinhua Hospital

Zhejiang University School of Medicine

Establishing a Competing Risk Regression Nomogram Model for Survival Data

An R-Based Landscape Validation of a Competing Risk Model

Hongjuan Zheng

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Medical Oncology,Affiliated Jinhua Hospital,Department of Medical Oncology, Affiliated Jinhua Hospital

Zhejiang University School of Medicine

Establishing a Competing Risk Regression Nomogram Model for Survival Data

An R-Based Landscape Validation of a Competing Risk Model

Department of Medical Oncology,
Affiliated Jinhua Hospital,
Department of Medical Oncology, Affiliated Jinhua Hospital